INT246089

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2008
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.42
Pain Relevance 1.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MAOA) small molecule metabolic process (MAOA) oxidoreductase activity (MAOA)
Anatomy Link Frequency
MT2 4
MAOA (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 69 100.00 Very High Very High Very High
Dopamine 21 100.00 Very High Very High Very High
monoamine 9 100.00 Very High Very High Very High
sSRI 22 99.92 Very High Very High Very High
antidepressant 74 96.00 Very High Very High Very High
Serotonin 14 93.56 High High
sNRI 8 91.56 High High
tricyclic antidepressant 7 82.44 Quite High
depression 104 80.12 Quite High
Catecholamine 3 44.84 Quite Low
Disease Link Frequency Relevance Heat
Psychosis 7 91.84 High High
Disease 118 85.20 High High
Confusion 1 83.40 Quite High
Hallucination 5 80.68 Quite High
Depression 122 80.12 Quite High
Sleep Disorders 26 73.44 Quite High
Diabetes Mellitus 1 67.00 Quite High
Pressure And Volume Under Development 3 66.60 Quite High
Cardiovascular Disease 1 66.04 Quite High
Dementia 5 64.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, selective and reversible inhibitors of the monoamine oxidase A, an irreversible monoamine oxidase B inhibitor, nonselective and irreversible inhibitors of the monoamine oxidase, selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors, and antidepressants with a dual mode of action such as selective serotonin and norepinephrine reuptake inhibitors (SNRI), and noradrenergic and specific serotonergic antidepressants acting via blockade of alfa2 and 5-HT2 receptors, are all available.13–17 The most recently investigated mechanism of action is the agonism at melatonergic MT1 and MT2 receptors and selective antagonism at serotonergic 5-HT2C receptors represented by the antidepressant agomelatine,5 which is currently under review by authorities in Europe.


Spec (investigated) Negative_regulation (inhibitor) of Negative_regulation (inhibitors) of monoamine oxidase in MT2 associated with antidepressant, snri, serotonin, ssri and monoamine
1) Confidence 0.41 Published 2010 Journal Core evidence Section Body Doc Link PMC2899775 Disease Relevance 0.44 Pain Relevance 0.83
In addition, selective and reversible inhibitors of the monoamine oxidase A, an irreversible monoamine oxidase B inhibitor, nonselective and irreversible inhibitors of the monoamine oxidase, selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors, and antidepressants with a dual mode of action such as selective serotonin and norepinephrine reuptake inhibitors (SNRI), and noradrenergic and specific serotonergic antidepressants acting via blockade of alfa2 and 5-HT2 receptors, are all available.13–17 The most recently investigated mechanism of action is the agonism at melatonergic MT1 and MT2 receptors and selective antagonism at serotonergic 5-HT2C receptors represented by the antidepressant agomelatine,5 which is currently under review by authorities in Europe.


Spec (investigated) Negative_regulation (inhibitors) of Spec (investigated) Negative_regulation (inhibitor) of monoamine oxidase in MT2 associated with antidepressant, snri, serotonin, ssri and monoamine
2) Confidence 0.41 Published 2010 Journal Core evidence Section Body Doc Link PMC2899775 Disease Relevance 0.46 Pain Relevance 0.84
Borek and colleagues (2007) suggested eliminating anticholinergics first, followed by amantadine, monoamine oxidase inhibitors, dopamine agonists, COMT inhibitors, then reducing the amount of levodopa.
Negative_regulation (reducing) of Negative_regulation (inhibitors) of monoamine oxidase associated with dopamine, agonist and monoamine
3) Confidence 0.10 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2536542 Disease Relevance 1.53 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox